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Highlights 
 
What’s new?  
Key findings 
 We propose a framework to classify meta-analysis with zero-events studies, which can 
clearly classify meta-analysis with zero-events studies into six subtypes; the classification 
matched well to the large real-world dataset. 
 Based on the proposed framework, we developed a flow diagram which presents the 
applicability of the existing methods for each type of meta-analysis with zero-events studies 
to guide synthesis practice. 
What this study adds to what is known? 
 In evidence synthesis practice for meta-analysis of adverse events, researchers often face the 
problem of how to deal with zero-events. They usually classify studies with zero-events as 
single-arm-zero-events studies and double-arm-zero-events studies as an effort to deal with 
zero-events. While in meta-analysis of evidence synthesis practice, referring to this 
classification is not the best strategy to select synthesis methods to deal with the problem of 
zero-events, which may lead to research waste and mislead healthcare practice. In this study, 
we propose a new framework to classify meta-analysis with zero-events studies to guide 
researchers to better deal with zero-events in meta-analysis. 
What are the implications, and what should be changed? 
 The proposed framework should be routinely considered by researchers when making 
decisions on the selection of the synthesis methods in a meta-analysis.  
 Statisticians and methodologists may add other existing methods or novel methods in our 
flow diagram to enhance selection of relevant methods for evidence synthesis. They can also 
compare the statistical properties of the methods under each subtype to provide more 
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Abstract 
Objective: In evidence synthesis practice, researchers often face the problem of how to deal with 
zero-events. Inappropriately dealing with zero-events studies may lead to research waste and 
mislead healthcare practice. We propose a framework to guide researchers to better deal with 
zero-events in meta-analysis. 
Study Design and Setting: We used two dimensions, one with respect to the total events count 
across all studies in the comparative arms in a meta-analysis, and a second with respect to whether 
included studies have single or both arms with zero-events, to establish the framework for the 
classification of meta-analysis with zero-events studies. A dataset from Cochrane systematic 
reviews was used to evaluate the classification.  
Results: The proposed framework classifies meta-analysis with zero-events studies into six 
subtypes. The classification matched well to the large real-world dataset. The applicability of 
existing methods for zero-events were then presented under each meta-analysis subtype based on 
this framework, with a 5-step principle to help researchers in evidence synthesis practice. 
Conclusions: The proposed framework should be considered by researchers when making 
decisions on the selection of the synthesis methods in a meta-analysis. It also provides a 
reasonable basis for the development of methodological guidelines to deal with zero-events in 
meta-analysis.  
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1. Introduction 
Meta-analysis has been widely used to synthesis evidence for studies of the same topic, 
through either a fixed-effect or a random-effect scheme, as an effort to obtain more precise and 
comprehensive results for decision-making. While for meta-analysis of rare events, researchers 
often face the problem of how to deal with zero-events. Zero-events generally occur when the risk 
of events is low, the sample size is small, or the follow-up period is short - these are frequently 
seen with safety outcomes [1-2]. In a survey of a random sample of 500 Cochrane systematic 
reviews, 30%-34.4% of the meta-analyses contained studies with zero-events [3, 4]. These 
zero-events pose special challenges for making statistical inferences in single trials as well as 
meta-analyses.  
Risk ratio (RR), odds ratio (OR), and risk difference (RD) are the most frequently used effect 
measures in meta-analyses of binary outcomes, where the RR and OR are relative measures and 
RD is an absolute measure [5]. In the presence of zero-events, it is difficult to properly calculate 
the RR and OR directly because their denominators are zero. This is not the case for the RD 
because it is the difference of two risks. However, the variances of all RR, OR, and RD could not 
be defined using the classical delta method. With advances in methodology, the estimation of the 
variance of RD for zero-events has been well-addressed [6, 7]. However, a universal consensus is 
still not achieved to handle zero-events for the RR and OR.  
In order to develop statistical models to deal with the problems posed by zero-events, 
researchers usually classify studies with zero-events into two groups: 1) single-arm-zero-events 
studies, where zero-events only occur in one of the arms; and 2) double-arm-zero-events studies, 
where zero-events occur in both arms. This classification provides a foundation for statisticians to 
investigate methods for handling zero-events; current recommendations for meta-analysis with 
zero-events also rely mainly on this classification to guide evidence synthesis. For example, in the 
Cochrane Handbook, Peto’s OR and Mantel–Haenszel (MH) methods are recommended to deal 
with single-arm-zero-events [5]. For double-arm-zero-events studies, most software automatically 
discard them from a meta-analysis (e.g., RevMan, current version 5.4.1 [8]). Some researchers 
claim that such studies are non-informative because they add nothing to the pooled effects of 
relative measures [9]. However, this practice could be problematic from both clinical and 
         
statistical points. First, double-arm-zero-events studies contribute an important source of evidence; 
discarding them is a deviation of the principle of evidence-based medicine and would lead to 
research waste. Second, such studies are not necessarily “non-informative,” depending on the 
methods used to synthesize them. For example, for studies with balanced sample sizes, 
zero-events in both arms indicate there are comparable treatment effects [10]. Our previous study 
has shown that excluding studies with no events in both arms can result in about 10% of the 
meta-analyses changed the statistical significance [11].  
We recognize that the currently used classification for studies with zero-events is not 
primarily aimed to guide meta-analysis, but to deal with zero-events in single studies. In 
meta-analysis of evidence synthesis practice, referring to this classification is therefore not the 
best strategy to deal with the problem of zero-events. In some cases, both single-arm-zero-events 
studies and double-arm-zero-events studies could be included in meta-analyses. Some methods 
(e.g., Peto’s OR) may provide a good solution to single-arm-zero-events studies, but they perform 
poorly in double-arm-zero-events studies, and vice versa [10, 12]. Systematic reviewers may 
become confused when choosing methods to deal with zero-events studies. More importantly, 
inappropriate choices in evidence synthesis cause research waste (e.g., discarding 
double-arm-zero-events) and could mislead healthcare practice. 
In this study, we propose a framework to classify meta-analysis with zero-events studies to 
provide a comprehensive and simple approach for meta-analysis practitioners. 
 
2. Classification for meta-analysis with zero-events studies 
On a meta-level basis, the proposed framework treats the whole meta-analysis as a unit, 
instead of each study as a unit, to classify meta-analysis with zero-events studies into different 
subtypes. The idea is driven from the classification method for single studies mentioned earlier. In 
order to better understand the framework, we first present the classification method for single 
studies: under single-arm-zero-events, the total events are zero in one of the arms; under 
double-arm-zero-events, the total events are zero in both arms. It can be seen that the classification 
is determined by the total events in each arm.  
Following this logic, in our meta-level framework, the total events count in each arm across 
         
studies is considered as one of the dimensions for the classification. This dimension defines two 
types of meta-analysis: 1) the total events count is zero in one arm or in both arms; and 2) the total 
events count is zero in neither arm (i.e., total events > 0 in both arms). The second type illustrates 
that even when the total events count is not zero in both arms, a meta-analysis could still contain 
studies with zero-events. Only using this dimension is therefore insufficient to clearly classify a 
meta-analysis, because for each of these two types of meta-analysis, single-arm-zero, 
double-arm-zero studies, or both could be involved, where different methods are required to deal 
with these different cases. Therefore, a second dimension is further needed to distinguish the 
distribution of zero-events studies in a meta-analysis: 1) meta-analysis with only 
single-arm-zero-events studies; 2) meta-analysis with only double-arm-zero-events studies; and 3) 
meta-analysis with a mixture of both single-arm-zero-events and double-arm-zero-events studies. 
These two dimensions can clearly classify meta-analysis with zero-events studies into six 
subtypes (2×3) as follows: 
1) MA-SZ: meta-analysis contains zero-events only occurring in single arms, no 
double-arm-zero-events studies are included, and the total events count in neither arm is zero; 
2) MA-MZ: meta-analysis contains zero-events occurring in both single and double arms, and 
the total events count in neither arm is zero; 
3) MA-DZ: meta-analysis contains zero-events only occurring in double arms, and the total 
events count in neither arm is zero; 
4) MA-CSZ: meta-analysis contains zero-events occurring in single arms, and no 
double-arm-zero-events studies are included, while the total events count in one of the arms is 
zero; 
5) MA-CMZ: meta-analysis contains zero-events occurring in both single arm and double arms, 
while the total events count in one of the arms is zero;  
6) MA-CDZ: meta-analysis only includes double-arm-zero-events studies, while the total events 
count in both arms are zero. 
Figure 1 illustrates the framework of the six subtypes of meta-analysis. In the above 
abbreviations, “MA” stands for meta-analysis, “S” for single arms, “M” for mixture of single arms 
and double arms, and “D” for double arms. Because subtypes 4-6 require that all included studies 
         
in a meta-analysis are zero-events studies, we define them as “completely zero-events-studies 
meta-analysis,” and “C” stands for “completely.” It should be noted that subtypes 1-3 may also 
only contain studies with zero-events, but studies without zero-events could be present. 
 
3. Rationale for the classification 
Differentiating meta-analyses with zero-events studies based on the two dimensions is in light 
of the applicability of current methods for meta-analysis. Current methods for zero-events studies 
can be classified as one-stage approaches or two-stage approaches. In a two-stage approach (also 
known as the standard meta-analysis approach), the study-specific effect sizes and standard errors 
are obtained or estimated from the included studies at the first stage, and then they are synthesized 
at the second stage [13, 14]. Under the two-stage approach, available methods for zero-events 
include the continuity/empirical correction [7], Peto’s OR [15], MH [16], two-stage Bayesian 
methods [17, 18], the exact p-function method [19], the arcsine-based transformation (e.g., arcsine 
difference [20]), etc. Among these methods, Peto’s OR is not applicable for dealing with 
double-zero-events studies. It should be noted that these methods are estimation methods used at 
the first stage to obtain the study-specific effects; strictly speaking, they are not meta-analytic 
methods since meta-analytic methods refer to as a type of “weighted average” procedure [5, 21, 
22]. For the one-stage approaches, there is no need to obtain study-specific effect sizes. Instead, 
each study is treated as a stratum or cluster, and the overall effect size can be obtained by the 
population average method [13, 14], which includes the generalized linear mixed models 
(GLMMs) [23, 24], the generalized estimating equations (GEEs) [25], the stratified exact 
regression [10], one-stage Bayesian methods [26], the beta-binominal methods [27], etc.  
One-stage approaches provide a valid solution to synthesize studies with zero-events, 
especially in the presence of studies with zero-events in both arms [23]. However, when the total 
events count in the meta-analysis is zero in one of the arms or both arms, one-stage approaches 
cannot be used for synthesis due to the problem of separation. For example, an empirical logistic 
regression could not be conducted in a single study with no events in one of the arms (or both 
arms). Therefore, for MA-CSZ, MA-CMZ, and MA-CDZ, most of the one-stage methods (e.g., 
GLMM, GEE, stratified exact regression) are not applicable. As such, we need to distinguish 
         
whether the total events count is zero at the meta-level (dimension 1).  
Unlike one-stage approaches, two-stage approaches generally provide a valid solution to 
synthesizing studies with zero-events in a single arm, but they are less preferable for studies with 
zero-events in both arms. As a result, without a prior information or post hoc correction, most of 
the two-stage methods are not appropriate to be used to measure relative risks in MA-MZ, MZ-DZ, 
MA-CMZ, and MA-CDZ. For example, the Peto’ OR, the MH OR/RR. For this reason, we must 
consider another dimension to distinguish meta-analysis with single-arm-zero-events studies, 
double-arm-zero-events studies, or both (dimension 2).  
Under our proposed framework, the applicability of each method can be clearly mapped to 
guide evidence synthesis practice. 
 
4. Real-world data for the classification 
We utilized data from Cochrane Database of Systematic Reviews (CDSR) to empirically 
assess the frequencies and proportions of each type of meta-analysis. Data from the CDSR 
containing meta-analyses published from January 2003 to May 2018 were collected; 
meta-analyses with two or more studies were considered. A detailed description for the data 
collection process has been documented elsewhere [28-30]. 
From 6,781 CDSRs, we obtained a total of 61,090 meta-analyses with binary outcomes, of 
which 21,288 meta-analyses were identified with zero-events studies (34.85%). We further 
summarized the frequency and proportion of each meta-analysis subtype with zero-event studies 
(Figure 2). The MA-SZ was the most common subset, including 19,308 (90.70%) meta-analyses; 
the MA-CSZ subset ranked the second, including 1,322 (6.21%) meta-analyses. The MA-MZ 
subset included 295 (1.39%) meta-analyses, and the MA-DZ subset included 147 (0.69%) 
meta-analyses. For both MA-CMZ and MA-CDZ subsets, 108 (0.51%) meta-analyses were 
identified. These real-world data support the relevance and appropriateness of the proposed 
classification framework.  
 
5. How to use the framework for evidence synthesis practice? 
Within the proposed framework, the degree of difficulty in synthesizing evidence increases 
         
gradually from subtype 1 to 6. For example, in subtype 1 of MA-SZ, almost all methods can be 
used to deal with zero-events for the synthesis; however, in subtype 6 of MA-CDZ, only a limited 
number of methods can be used. To help researchers to better understand how to apply existing 
methods to perform the research synthesis, we developed a flow diagram to guide synthesis 
practice under the proposed framework, as seen in Figure 3.  
This diagram lists the applicability of the aforementioned methods for each type of 
meta-analysis. For example, Peto’s OR could be used in MA-SZ and MA-CSZ, but is not suitable 
for MA-MZ, MA-DZ, MA-CMZ, and MA-CDZ where double-arm-zero-events studies are 
involved. The GLMMs could be used in MA-SZ, MA-MZ, and MA-DZ, but not in MA-CSZ, 
MA-CMZ, and MA-CDZ where the total events count is zero in either or both arms. Statisticians 
and methodologists may add other existing methods or novel methods in this flow diagram (where 
we marked “…” in the diagram) to enhance selection of relevant methods for evidence synthesis. 
They can also compare the statistical properties of the methods under each subtype to provide 
more concrete guidance for meta-analysis authors.   
For meta-analysis authors, the flow diagram clearly indicates which methods could be 
appropriately used under each classification. We recommend meta-analysis authors refer to the 
following 5 steps in Box 1 to conduct evidence synthesis practice for meta-analysis with 
zero-events studies. 







We used the meta-analysis by Liu et al. [31] as a real-world example to illustrate how the 
framework works. This meta-analysis assessed the safety of glucagon-like peptide-1 receptor 
agonists and dipeptidyl peptidase-4 inhibitors on mortality for patients with type-2 diabetes. We 
used the data for vildagliptin (versus placebo, lifestyle modification, or active anti-hyperglycemic 
1. Check for zero-events studies;  
2. Check the framework of the classification to identify the meta-analysis belongs to which of 
MA-SZ, MA-MZ, MA-DZ, MA-CSZ, MA-CMZ, and MA-CDZ;  
3. Check all available methods that could be used under the classification in the flow diagram;  
4. Conduct the meta-analysis by using one or more appropriate methods;  
5. Conduct sensitivity analysis using other available methods to test whether the results are 
robust. 
         
drugs) which consisted of 26 randomized controlled trials (Figure 4). It should be noted that this is 
an extreme example because the event rate was very low and it contained a mega trial.  
Step 1. We identified that the dataset contains 13 trials with zero-events occurring in both 
arms and 6 trials with zero-events occurring in a single arm. The total events count 
in neither arm is zero.  
Step 2. According to our proposed framework, this meta-analysis is classified as MA-MZ.  
Step 3. Using the flow diagram, we identify that there are at least 9 methods to deal with 
this type of meta-analysis.  
Step 4. We used the MH methods with RD as an effect measure in the main analysis. In 
order increase the statistical power to detect a signal of adverse events, we used the 
fixed-effect analytic model for pooling [32].  
Step 5. An empirical correction [7] with the fixed-effect analytic model was used as the 
first sensitivity analysis. The random-intercept GLMM method (random baseline 
risks but fixed treatment effect) [11] under the one-stage framework was used as 
the second sensitivity analysis.  
The MetaXL 5.3 software (EpiGear International Pty Ltd, Australian) and R 3.51 (R 
foundation) were used for the analyses. Figure 4 presents the pooled results for the main analysis. 
The pooled RD for mortality on vildagliptin compared to control was -0.001 (95%CI: -0.004, 
0.002, p=0.43). Our two sensitivity analyses confirmed the results. We may further show the 
potential research waste by excluding 13 studies with zero-events occurring in both arms with the 
same analytic method: the pooled RD was -0.001 (95%CI: -0.005, 0.002, p=0.36). In this case, 




We propose a practical framework to classify meta-analysis with zero-events studies, which is 
useful for meta-analysis authors when they face the problem of zero-events. Based on this 
framework, we estimated the frequencies of each subtype of meta-analysis with zero-events 
studies in a large real-world dataset and found that our theoretical framework had a good match. 
         
We further developed a 5-step principle to guide researchers to use the framework and select 
appropriate methods for meta-analysis. Our framework will provide a reasonable basis for the 
development of methodological guidelines to deal with zero-events in meta-analysis. 
In the flow diagram, we did not list the methods for relative and absolute measures separately. 
Instead, we indicated which methods could be used with absolute risk (e.g., RD) or relative 
measures (e.g., Peto’s OR) for the synthesis under the six subtypes of meta-analysis. For example, 
we indicated that for MA-MZ, MA-DZ, MA-CMZ, and MA-CDZ, the MH can be used for 
synthesis when measuring the effect by the RD, because double-arm-zero-events studies would be 
automatically discarded when the MH method with OR/RR is utilized. It should be noted that, 
except for the situation that all the included studies have zero cell in the same arm, the 
single-arm-zero-studies do not require a continuity correction under MH method [5, 7]. While in 
most of the software, a continuity correction is routinely employed for MH OR/RR. Indeed, the 
RD is an appealing effect estimator to deal with zero-events over the OR and RR as neither prior 
information nor post hoc correction is needed. One can also use the RD to estimate the number 
needed to treat (NNT) to reflect the average number of patients who need to be treated to prevent 
one additional harmful outcome. While empirical evidence suggested that RD may increase the 
heterogeneity than OR and RR [33], at least, this may lead to the downgrade of the confidence of 
the evidence [34]. There is currently no consensus about the selection of effect estimator for rare 
events. But it is clear that the non-reporting problem of the events contributes a major source of 
systematic error that may biased the effect estimates, regardless of the OR, RR, and RD.  
Notably, the continuity/empirical correction is not routinely employed for studies with no 
events in both arms; this requires researchers to indicate such a scheme or do it manually in the 
program. Moreover, several methods (e.g., GLMM, beta-binominal) listed in the flow diagram are 
not available in many meta-analytical programs, but they can be done by other programs (e.g., 
meglm, betabin in Stata, lme4 in R). Researchers are highly recommended to collaborate with 
methodologists or statisticians when conducting zero-events meta-analysis. The flow diagram 
provides a group of methods for each type of meta-analysis, thus further investigation is needed to 
determine which method would perform better within each meta-analysis type. 
It should be highlighted that this framework is based on post hoc classification. This means 
         
systematic reviewers can only determine the subtype after the data for a meta-analysis are 
obtained. Researchers cannot use this framework to help them to make an a priori synthesis plan 
as they do not know which subtype of meta-analysis (with zero-events) they will be facing. 
However, it is highly recommended for authors to develop a synthesis plan in advance to avoid 
selective reporting, including for meta-analysis that may involve zero-events [35, 36]. One 
possible and practical solution is that researchers consider all six possible situations a priori and 
pre-define one or more available methods for each situation in their protocols.  
In the 5-step principle, we recommend that researchers conduct a sensitivity analysis by using 
other available synthesis methods. We recommend this based on the consideration of the unstable 
nature of such types of meta-analysis as the total events in both arms are still rare, leading to a 
large amount of uncertainty for inference. Once there are conflicting results in sensitivity analysis, 
there is currently no well-established evidence to support a preferred conclusion. However, for 
safety outcome, the “at worst” principle could be considered that the one presenting a more 
obvious signal of harms is the first concern [5]. In addition, two additional recommendations 
beyond the framework are worthwhile for consideration. First, before the evidence synthesis, we 
recommend researchers to estimate the minimal sample size for detecting a potential difference 
[37, 38]. In some situations, statistically non-significant results may be due to an insufficient 
sample size, not to a true non-significant difference. Researchers have advocated that putting too 
much focus on statistical significance is not desirable [39]. Second, the GRADE (Grading of 
Recommendations, Assessment, Development and Evaluations) system [34] or other similar 
ranking systems should be used to grade the certainty of the results; this can be judged along with 
the power-analysis results. 
For the selection of concrete methods to deal with zero-events studies, there is currently no 
universal consensus on which method should be used. A specific recommendation on concrete 
methods under each subtype may be unrealistic at present. However, we may offer some practices 
to be avoided as follows, which could be useful for future systematic reviewers. First, it is not 
recommended to use continuity correction (adding 0.5) when the sample sizes of the two arms are 
imbalanced (e.g., 1:2) because well-established evidence has shown that it would lead to large bias 
or even reverse the effects [7]. The empirical correction could be an alternative for continuity 
         
correction in this case [7]. Second, it is not recommended to use Bayesian methods when most or 
all the included studies are both-arm-zero-events studies. This is because posterior estimates are 
susceptible to the prior distribution as the weight of sample information is small, even if 
non-informative prior is used in such case [11]. Third, it is not recommended to use the 
“treat-as-one-trial” method, say, adding the cases and sample sizes together of included studies, as 
this would lead to Simpson’s paradox and mislead the healthcare practice [40]. Fourth, for safety 
outcomes, it is not suggested to use the conservative analytic model (e.g., random-effects model). 
This has been clarified by Poole & Greenland [31] and in the Cochrane Handbook [5]. As the 
Cochrane Handbook documented: “incorporation of heterogeneity into an estimate of a treatment 
effect should be a secondary consideration when attempting to produce estimates of effects from 




Meta-analysis with zero-events studies represents a difficult and complex issue in evidence 
synthesis practice. The framework we proposed could be considered for researchers to make better 
decisions on the selection of the synthesis methods in their meta-analysis. This framework could 
be useful for statisticians to examine the properties and applicability of various methods for 
meta-analysis with zero-events studies. In addition, our framework provides a reasonable basis for 
the development of methodological guidelines to deal with zero-events in meta-analysis.  
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Figure Legends 
 
Figure 1. The proposed framework for meta-analysis with zero-events studies. 
  
         
 
Figure 2. Proportion of each type of meta-analysis with zero-events studies based on the proposed 
framework. 
  
         
 
Figure 3. Flow diagram to guide evidence synthesis practice. 
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